KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Gains from Sales and Divestitures: 2019-2020

Historic Gains from Sales and Divestitures for Novavax (NVAX) over the last 1 years, with Sep 2020 value amounting to $781,812.

  • Novavax's Gains from Sales and Divestitures rose 976.33% to $781,812 in Q3 2020 from the same period last year, while for Sep 2020 it was $781,812, marking a year-over-year increase of 976.33%. This contributed to the annual value of $72,637 for FY2019, which is N/A change from last year.
  • Latest data reveals that Novavax reported Gains from Sales and Divestitures of $781,812 as of Q3 2020, which was up 1,543.74% from $47,563 recorded in Q2 2020.
  • In the past 5 years, Novavax's Gains from Sales and Divestitures ranged from a high of $781,812 in Q3 2020 and a low of $17,563 during Q1 2020.
  • Moreover, its 2-year median value for Gains from Sales and Divestitures was $72,637 (2019), whereas its average is $198,442.
  • Data for Novavax's Gains from Sales and Divestitures shows a peak YoY spiked of 976.33% (in 2020) over the last 5 years.
  • Novavax's Gains from Sales and Divestitures (Quarterly) stood at $72,637 in 2019, then spiked by 976.33% to $781,812 in 2020.
  • Its Gains from Sales and Divestitures stands at $781,812 for Q3 2020, versus $47,563 for Q2 2020 and $17,563 for Q1 2020.